<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="interaction" /><meta name="keywords" content="" /><title>Isocarboxazid: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="bnf_int258-isocarboxazid.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="bnf_int258-isocarboxazid.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=bnf_int258-isocarboxazid.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 07 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP8848-interactions.htm">Appendix 1 Interactions</a> &gt; <a href="PHP8852-list-of-drug-interactions.htm">List of drug interactions</a> &gt; <a href="bnf_int229-antidepressants.htm">Antidepressants</a> &gt; <a href="bnf_int257-maois.htm">MAOIs</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="bnf_int257-maois.htm" title="Previous: MAOIs">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="bnf_int259-phenelzine.htm" title="Next: Phenelzine">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1>Isocarboxazid</h1><?highlighter on?><div id="pC" class="jN"><p><strong>Isocarboxazid</strong> has no specific interaction information.</p><p><strong>Isocarboxazid</strong> belongs to <strong>MAOIs</strong> and will have the following interaction information:</p><div class="cG"><p><strong>Note:</strong> For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</p></div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int2-ace-inhibitors.htm">ACE Inhibitors</a></td><td><p><span></span> <span>MAOIs</span> <span>possibly enhance hypotensive effect of</span> <span>ACE inhibitors</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int15-adrenergic-neurone-blockers.htm">Adrenergic Neurone Blockers</a></td><td><p><span>enhanced hypotensive effect when </span> <span>MAOIs</span> <span>given with</span> <span>adrenergic neurone blockers</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int20-alcohol.htm">Alcohol</a></td><td class="cAI"><p><span></span> <span>MAOIs</span> <span>interact with tyramine found in some beverages containing</span> <span>alcohol</span> <span>and some dealcoholised beverages (hypertensive crisis)—if no tyramine, enhanced hypotensive effect</span>  </p></td><td></td></tr><tr><td><a href="bnf_int26-alpha-blockers.htm">Alpha-blockers</a></td><td><p><span>enhanced hypotensive effect when </span> <span>MAOIs</span> <span>given with</span> <span>alpha-blockers</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int107-angiotensin-ii-receptor-antagonists.htm">Angiotensin-II Receptor Antagonists</a></td><td><p><span></span> <span>MAOIs</span> <span>possibly enhance hypotensive effect of</span> <span>angiotensin-II receptor antagonists</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int232-antidepressants-ssri.htm">Antidepressants, SSRI</a></td><td class="cAI"><p><span></span> <span>MAOIs</span> <span>increase CNS effects of</span> <span>SSRIs</span> <span>(risk of serious toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int241-antidepressants-tricyclic.htm">Antidepressants, Tricyclic</a></td><td class="cAI"><p><span>increased risk of hypertension and CNS excitation when </span> <span>MAOIs</span> <span>given with</span> <span>tricyclics</span> <span>, <span>tricyclics</span> should not be started until 2 weeks after stopping <span>MAOIs</span> (3 weeks if starting clomipramine or imipramine), also <span>MAOIs</span> should not be started for at least 1–2 weeks after stopping <span>tricyclics</span> (3 weeks in the case of clomipramine or imipramine)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int252-antidepressants-tricyclic-related.htm">Antidepressants, Tricyclic (related)</a></td><td class="cAI"><p><span>after stopping </span> <span>MAOIs</span> <span>do not start</span> <span>tricyclic-related antidepressants</span> <span>for 2 weeks, also <span>MAOIs</span> should not be started until at least 1–2 weeks after stopping <span>tricyclic-related antidepressants</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int264-antidiabetics.htm">Antidiabetics</a></td><td><p><span></span> <span>MAOIs</span> <span>possibly enhance hypoglycaemic effect of</span> <span>antidiabetics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int276-antiepileptics.htm">Antiepileptics</a></td><td><p><span></span> <span>MAOIs</span> <span>possibly antagonise anticonvulsant effect of</span> <span>antiepileptics</span> <span>(convulsive threshold lowered)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int303-antihistamines.htm">Antihistamines</a></td><td><p><span>increased antimuscarinic and sedative effects when </span> <span>MAOIs</span> <span>given with</span> <span>antihistamines</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Sedative interactions apply to a lesser extent to the non-sedating antihistamines. Interactions do not generally apply to antihistamines used for topical action (including inhalation)</p></div></td></tr><tr><td><a href="bnf_int342-antimuscarinics.htm">Antimuscarinics</a></td><td><p><span>increased risk of antimuscarinic side-effects when </span> <span>MAOIs</span> <span>given with</span> <span>antimuscarinics</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Many drugs have antimuscarinic effects; concomitant use of two or more such drugs can increase side-effects such as dry mouth, urine retention, and constipation; concomitant use can also lead to confusion in the elderly. Interactions do not generally apply to antimuscarinics used by inhalation</p></div></td></tr><tr><td><a href="bnf_int24-apraclonidine.htm">Apraclonidine</a></td><td><p><span>avoidance of </span> <span>MAOIs</span> <span>advised by manufacturer of</span> <span>apraclonidine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1009-atomoxetine.htm">Atomoxetine</a></td><td class="cAI"><p><span>after stopping </span> <span>MAOIs</span> <span>do not start</span> <span>atomoxetine</span> <span>for 2 weeks, also <span>MAOIs</span> should not be started until at least 2 weeks after stopping <span>atomoxetine</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int440-beta-blockers.htm">Beta-blockers</a></td><td><p><span>enhanced hypotensive effect when </span> <span>MAOIs</span> <span>given with</span> <span>beta-blockers</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Since systemic absorption may follow topical application of beta-blockers to the eye the possibility of interactions, in particular, with drugs such as verapamil should be borne in mind</p></div></td></tr><tr><td><a href="bnf_int25-brimonidine.htm">Brimonidine</a></td><td><p><span>avoidance of </span> <span>MAOIs</span> <span>advised by manufacturer of</span> <span>brimonidine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int896-bupropion.htm">Bupropion</a></td><td class="cAI"><p><span>avoidance of bupropion for 2 weeks after stopping </span> <span>MAOIs</span> <span>advised by manufacturer of</span> <span>bupropion</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int427-buspirone.htm">Buspirone</a></td><td><p><span>avoidance of </span> <span>MAOIs</span> <span>advised by manufacturer of</span> <span>buspirone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int466-calcium-channel-blockers.htm">Calcium-channel Blockers</a></td><td><p><span>enhanced hypotensive effect when </span> <span>MAOIs</span> <span>given with</span> <span>calcium-channel blockers</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Dihydropyridine calcium-channel blockers include amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and nimodipine</p></div></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td class="cAI"><p><span>avoidance for 2 weeks after stopping </span> <span>MAOIs</span> <span>advised by manufacturer of</span> <span>carbamazepine</span> <span>, also antagonism of anticonvulsant effect</span>  </p></td><td></td></tr><tr><td><a href="bnf_int233-citalopram.htm">Citalopram</a></td><td class="cAI"><p><span>after stopping </span> <span>MAOIs</span> <span>do not start</span> <span>citalopram</span> <span>for 2 weeks, also <span>MAOIs</span> should not be started until at least 1 week after stopping <span>citalopram</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int482-clonidine.htm">Clonidine</a></td><td><p><span>enhanced hypotensive effect when </span> <span>MAOIs</span> <span>given with</span> <span>clonidine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int364-clozapine.htm">Clozapine</a></td><td class="cAI"><p><span>CNS effects of </span> <span>MAOIs</span> <span>possibly increased by</span> <span>clozapine</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</p></div></td></tr><tr><td><a href="bnf_int522-diazoxide.htm">Diazoxide</a></td><td><p><span>enhanced hypotensive effect when </span> <span>MAOIs</span> <span>given with</span> <span>diazoxide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int524-diuretics.htm">Diuretics</a></td><td><p><span>enhanced hypotensive effect when </span> <span>MAOIs</span> <span>given with</span> <span>diuretics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int561-doxapram.htm">Doxapram</a></td><td><p><span></span> <span>MAOIs</span> <span>enhance effects of</span> <span>doxapram</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1024-duloxetine.htm">Duloxetine</a></td><td class="cAI"><p><span>after stopping </span> <span>MAOIs</span> <span>do not start</span> <span>duloxetine</span> <span>for 2 weeks, also <span>MAOIs</span> should not be started until at least 5 days after stopping <span>duloxetine</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int854-entacapone.htm">Entacapone</a></td><td class="cAI"><p><span>avoid concomitant use of non-selective </span> <span>MAOIs</span> <span>with</span> <span>entacapone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int964-escitalopram.htm">Escitalopram</a></td><td class="cAI"><p><span>after stopping </span> <span>MAOIs</span> <span>do not start</span> <span>escitalopram</span> <span>for 2 weeks, also <span>MAOIs</span> should not be started until at least 1 week after stopping <span>escitalopram</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int234-fluoxetine.htm">Fluoxetine</a></td><td class="cAI"><p><span>after stopping </span> <span>MAOIs</span> <span>do not start</span> <span>fluoxetine</span> <span>for 2 weeks, also <span>MAOIs</span> should not be started until at least 5 weeks after stopping <span>fluoxetine</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int235-fluvoxamine.htm">Fluvoxamine</a></td><td class="cAI"><p><span>after stopping </span> <span>MAOIs</span> <span>do not start</span> <span>fluvoxamine</span> <span>for 2 weeks, also <span>MAOIs</span> should not be started until at least 1 week after stopping <span>fluvoxamine</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1180-histamine.htm">Histamine</a></td><td><p><span>avoidance of </span> <span>MAOIs</span> <span>advised by manufacturer of</span> <span>histamine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int763-hydralazine.htm">Hydralazine</a></td><td><p><span>enhanced hypotensive effect when </span> <span>MAOIs</span> <span>given with</span> <span>hydralazine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int28-indoramin.htm">Indoramin</a></td><td class="cAI"><p><span>avoidance of </span> <span>MAOIs</span> <span>advised by manufacturer of</span> <span>indoramin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int265-insulin.htm">Insulin</a></td><td><p><span></span> <span>MAOIs</span> <span>enhance hypoglycaemic effect of</span> <span>insulin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int558-levodopa.htm">Levodopa</a></td><td class="cAI"><p><span>risk of hypertensive crisis when </span> <span>MAOIs</span> <span>given with</span> <span>levodopa</span> <span>, avoid <span>levodopa</span> for at least 2 weeks after stopping <span>MAOIs</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int257-maois.htm">MAOIs</a></td><td class="cAI"><p><span>increased risk of hypertension and CNS excitation when </span> <span>MAOIs</span> <span>given with other</span> <span>MAOIs</span> <span>(avoid for at least 2 weeks after stopping previous <span>MAOIs</span> and then start at a reduced dose)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</p></div></td></tr><tr><td><a href="bnf_int267-metformin.htm">Metformin</a></td><td><p><span></span> <span>MAOIs</span> <span>enhance hypoglycaemic effect of</span> <span>metformin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int611-methyldopa.htm">Methyldopa</a></td><td class="cAI"><p><span>avoidance of </span> <span>MAOIs</span> <span>advised by manufacturer of</span> <span>methyldopa</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int718-methylphenidate.htm">Methylphenidate</a></td><td class="cAI"><p><span>risk of hypertensive crisis when </span> <span>MAOIs</span> <span>given with</span> <span>methylphenidate</span> <span>, some manufacturers advise avoid <span>methylphenidate</span> for at least 2 weeks after stopping <span>MAOIs</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int764-minoxidil.htm">Minoxidil</a></td><td><p><span>enhanced hypotensive effect when </span> <span>MAOIs</span> <span>given with</span> <span>minoxidil</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int823-mirtazapine.htm">Mirtazapine</a></td><td class="cAI"><p><span>after stopping </span> <span>MAOIs</span> <span>do not start</span> <span>mirtazapine</span> <span>for 2 weeks, also <span>MAOIs</span> should not be started until at least 2 weeks after stopping <span>mirtazapine</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int262-moclobemide.htm">Moclobemide</a></td><td class="cAI"><p><span>after stopping </span> <span>MAOIs</span> <span>do not start</span> <span>moclobemide</span> <span>for at least 1 week</span>  </p></td><td></td></tr><tr><td><a href="bnf_int615-moxonidine.htm">Moxonidine</a></td><td><p><span>enhanced hypotensive effect when </span> <span>MAOIs</span> <span>given with</span> <span>moxonidine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int58-nefopam.htm">Nefopam</a></td><td class="cAI"><p><span>avoidance of </span> <span>MAOIs</span> <span>advised by manufacturer of</span> <span>nefopam</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int630-nicorandil.htm">Nicorandil</a></td><td><p><span>enhanced hypotensive effect when </span> <span>MAOIs</span> <span>given with</span> <span>nicorandil</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int631-nitrates.htm">Nitrates</a></td><td><p><span>enhanced hypotensive effect when </span> <span>MAOIs</span> <span>given with</span> <span>nitrates</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int85-opioid-analgesics.htm">Opioid Analgesics</a></td><td class="cAI"><p><span>possible CNS excitation or depression (hypertension or hypotension) when </span> <span>MAOIs</span> <span>given with</span> <span>opioid analgesics</span> <span>—some manufacturers advise avoid concomitant use and for 2 weeks after stopping <span>MAOIs</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int236-paroxetine.htm">Paroxetine</a></td><td class="cAI"><p><span>after stopping </span> <span>MAOIs</span> <span>do not start</span> <span>paroxetine</span> <span>for 2 weeks, also <span>MAOIs</span> should not be started until at least 1 week after stopping <span>paroxetine</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int102-pethidine.htm">Pethidine</a></td><td class="cAI"><p><span>CNS excitation or depression (hypertension or hypotension) when </span> <span>MAOIs</span> <span>given with</span> <span>pethidine</span> <span>—avoid concomitant use and for 2 weeks after stopping <span>MAOIs</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1185-pholcodine.htm">Pholcodine</a></td><td><p><span>avoidance of pholcodine for 2 weeks after stopping </span> <span>MAOIs</span> <span>advised by manufacturer of</span> <span>pholcodine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int325-promethazine.htm">Promethazine</a></td><td><p><span>avoidance of promethazine for 2 weeks after stopping </span> <span>MAOIs</span> <span>advised by manufacturer of</span> <span>promethazine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1051-rasagiline.htm">Rasagiline</a></td><td class="cAI"><p><span>risk of hypertensive crisis when </span> <span>MAOIs</span> <span>given with</span> <span>rasagiline</span> <span>, avoid <span>MAOIs</span> for at least 2 weeks after stopping <span>rasagiline</span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Rasagiline is a MAO-B inhibitor</p></div></td></tr><tr><td><a href="bnf_int231-reboxetine.htm">Reboxetine</a></td><td class="cAI"><p><span>increased risk of hypertension and CNS excitation when </span> <span>MAOIs</span> <span>given with</span> <span>reboxetine</span> <span>(<span>MAOIs</span> should not be started until 1 week after stopping <span>reboxetine</span>, avoid <span>reboxetine</span> for 2 weeks after stopping <span>MAOIs</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int862-rizatriptan.htm">Rizatriptan</a></td><td class="cAI"><p><span>risk of CNS toxicity when </span> <span>MAOIs</span> <span>given with</span> <span>rizatriptan</span> <span>(avoid <span>rizatriptan</span> for 2 weeks after <span>MAOIs</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int687-selegiline.htm">Selegiline</a></td><td class="cAI"><p><span>enhanced hypotensive effect when </span> <span>MAOIs</span> <span>given with</span> <span>selegiline</span> <span>—manufacturer of <span>selegiline</span> advises avoid concomitant use</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Selegiline is a MAO-B inhibitor</p></div></td></tr><tr><td><a href="bnf_int237-sertraline.htm">Sertraline</a></td><td class="cAI"><p><span>after stopping </span> <span>MAOIs</span> <span>do not start</span> <span>sertraline</span> <span>for 2 weeks, also <span>MAOIs</span> should not be started until at least 1 week after stopping <span>sertraline</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int765-sodium-nitroprusside.htm">Sodium Nitroprusside</a></td><td><p><span>enhanced hypotensive effect when </span> <span>MAOIs</span> <span>given with</span> <span>sodium nitroprusside</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int268-sulfonylureas.htm">Sulfonylureas</a></td><td><p><span></span> <span>MAOIs</span> <span>enhance hypoglycaemic effect of</span> <span>sulfonylureas</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int574-sumatriptan.htm">Sumatriptan</a></td><td class="cAI"><p><span>risk of CNS toxicity when </span> <span>MAOIs</span> <span>given with</span> <span>sumatriptan</span> <span>(avoid <span>sumatriptan</span> for 2 weeks after <span>MAOIs</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int690-sympathomimetics.htm">Sympathomimetics</a></td><td class="cAI"><p><span>risk of hypertensive crisis when </span> <span>MAOIs</span> <span>given with</span> <span>sympathomimetics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int733-tetrabenazine.htm">Tetrabenazine</a></td><td class="cAI"><p><span>risk of CNS toxicity when </span> <span>MAOIs</span> <span>given with</span> <span>tetrabenazine</span> <span>(avoid <span>tetrabenazine</span> for 2 weeks after <span>MAOIs</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1042-tolcapone.htm">Tolcapone</a></td><td><p><span>avoid concomitant use of </span> <span>MAOIs</span> <span>with</span> <span>tolcapone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int106-tramadol.htm">Tramadol</a></td><td class="cAI"><p><span>possible increased serotonergic effects and increased risk of convulsions when </span> <span>MAOIs</span> <span>given with</span> <span>tramadol</span> <span>—some manufacturers advise avoid concomitant use and for 2 weeks after stopping <span>MAOIs</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int263-tryptophan.htm">Tryptophan</a></td><td class="cAI"><p><span>CNS excitation and confusion when </span> <span>MAOIs</span> <span>given with</span> <span>tryptophan</span> <span>(reduce dose of <span>tryptophan</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int240-venlafaxine.htm">Venlafaxine</a></td><td class="cAI"><p><span>enhanced CNS effects and toxicity when </span> <span>MAOIs</span> <span>given with</span> <span>venlafaxine</span> <span>(<span>venlafaxine</span> should not be started until 2 weeks after stopping <span>MAOIs</span>, avoid <span>MAOIs</span> for 1 week after stopping <span>venlafaxine</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int575-zolmitriptan.htm">Zolmitriptan</a></td><td class="cAI"><p><span>increased risk of CNS toxicity when </span> <span>MAOIs</span> <span>given with</span> <span>zolmitriptan</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Isocarboxazid</strong> belongs to <strong>Antidepressants</strong> and will have the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int937-artemether-with-lumefantrine.htm">Artemether with Lumefantrine</a></td><td class="cAI"><p><span>avoidance of </span> <span>antidepressants</span> <span>advised by manufacturer of</span> <span>artemether/lumefantrine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1009-atomoxetine.htm">Atomoxetine</a></td><td><p><span>possible increased risk of convulsions when </span> <span>antidepressants</span> <span>given with</span> <span>atomoxetine</span> <span></span>  </p></td><td></td></tr></tbody></table></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="bnf_int257-maois.htm">Previous: MAOIs</a> | <a class="top" href="bnf_int258-isocarboxazid.htm#">Top</a> | <a accesskey="]" href="bnf_int259-phenelzine.htm">Next: Phenelzine</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>